GOLD | Large Healthcare Agency of 2017

Those numbers are especially impressive given the agency absorbed a $22 million loss after Novavax’s RSV vaccine failed its Phase III study and Lilly’s promising Alzheimer’s compound also fell short.

Judges were clearly impressed by the growth, but they also praised the agency’s highly respected management team and its very provocative work. 

Client testimonials also expressed high regard for the firm’s creative work, as well as its creative thinking, passion, and commitment. Certainly, Area 23 delivered powerful work to a variety of clients last year.

Leave a Reply

Your email address will not be published. Required fields are marked *